Cargando…

Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial

BACKGROUND: Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial evaluated the efficacy and toxicity of docetaxel plus cisplatin, as salvage chemotherapy in patients with M...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Se Hoon, Cho, Eun Kyung, Bang, Soo-Mee, Shin, Dong Bok, Lee, Jae Hoon, Lee, Young Don
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553982/
https://www.ncbi.nlm.nih.gov/pubmed/15723709
http://dx.doi.org/10.1186/1471-2407-5-21
_version_ 1782122496126877696
author Park, Se Hoon
Cho, Eun Kyung
Bang, Soo-Mee
Shin, Dong Bok
Lee, Jae Hoon
Lee, Young Don
author_facet Park, Se Hoon
Cho, Eun Kyung
Bang, Soo-Mee
Shin, Dong Bok
Lee, Jae Hoon
Lee, Young Don
author_sort Park, Se Hoon
collection PubMed
description BACKGROUND: Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial evaluated the efficacy and toxicity of docetaxel plus cisplatin, as salvage chemotherapy in patients with MBC resistant to prior anthracyclines. METHODS: Patients with MBC that had progressed after at least one prior chemotherapy regimen containing anthracyclines received docetaxel 75 mg/m(2 )followed by cisplatin 60 mg/m(2 )every 3 weeks for a maximum of 6 cycles or until disease progression. RESULTS: Between Jan 2000 and May 2002, 24 patients with tumors primary resistant and 15 with secondary resistant disease were accrued. All 39 patients were evaluable for safety and 36 for efficacy. The objective response rate was 31% (95% CI, 16–45%) with 3 complete responses. The median time to disease progression was 7 months, and the median overall survival was 23 months (median follow-up of 41 months). Neutropenia was the most frequently observed severe hematologic toxicity (39% of patients), whereas asthenia and nausea were the most common non-hematologic toxicities. No treatment-related death was observed. CONCLUSION: In conclusion, we found docetaxel plus cisplatin to be an active and safe chemotherapy regimen for patients with MBC resistant to anthracyclines.
format Text
id pubmed-553982
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-5539822005-03-11 Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial Park, Se Hoon Cho, Eun Kyung Bang, Soo-Mee Shin, Dong Bok Lee, Jae Hoon Lee, Young Don BMC Cancer Research Article BACKGROUND: Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial evaluated the efficacy and toxicity of docetaxel plus cisplatin, as salvage chemotherapy in patients with MBC resistant to prior anthracyclines. METHODS: Patients with MBC that had progressed after at least one prior chemotherapy regimen containing anthracyclines received docetaxel 75 mg/m(2 )followed by cisplatin 60 mg/m(2 )every 3 weeks for a maximum of 6 cycles or until disease progression. RESULTS: Between Jan 2000 and May 2002, 24 patients with tumors primary resistant and 15 with secondary resistant disease were accrued. All 39 patients were evaluable for safety and 36 for efficacy. The objective response rate was 31% (95% CI, 16–45%) with 3 complete responses. The median time to disease progression was 7 months, and the median overall survival was 23 months (median follow-up of 41 months). Neutropenia was the most frequently observed severe hematologic toxicity (39% of patients), whereas asthenia and nausea were the most common non-hematologic toxicities. No treatment-related death was observed. CONCLUSION: In conclusion, we found docetaxel plus cisplatin to be an active and safe chemotherapy regimen for patients with MBC resistant to anthracyclines. BioMed Central 2005-02-22 /pmc/articles/PMC553982/ /pubmed/15723709 http://dx.doi.org/10.1186/1471-2407-5-21 Text en Copyright © 2005 Park et al; licensee BioMed Central Ltd.
spellingShingle Research Article
Park, Se Hoon
Cho, Eun Kyung
Bang, Soo-Mee
Shin, Dong Bok
Lee, Jae Hoon
Lee, Young Don
Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
title Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
title_full Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
title_fullStr Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
title_full_unstemmed Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
title_short Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
title_sort docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase ii clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553982/
https://www.ncbi.nlm.nih.gov/pubmed/15723709
http://dx.doi.org/10.1186/1471-2407-5-21
work_keys_str_mv AT parksehoon docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial
AT choeunkyung docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial
AT bangsoomee docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial
AT shindongbok docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial
AT leejaehoon docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial
AT leeyoungdon docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial